In 2017, FDA granted approval of GO with 2 indications: (1) treatment of newly diagnosed CD33-positive AML in adults in combination with DNR and ARA-C at 3 mg/m2 (up to 5 mg) on days 1, 4, and 7 or as single-agent regimen at 6 mg/m2 on day 1 and 3 mg/m2 on Day 8; and (2) treatment of relapsed or refractory CD33-positive AML in adults and in pediatric patients >2 years at 3 mg/m2 on days 1, 4, and 7 [60,61]. Here, CD33 is linked to acute myeloid leukemia.